First Successful Transapical Aortic Valve Implantation with the Corevalve <i>Revalving™</i> System: A Case Report
DOI:
https://doi.org/10.1532/HSF98.20071140Abstract
On June 26, 2007, the Clinic for Cardiovascular Surgery at the German Heart Center Technical University in Munich successfully implanted a bioprosthetic valve via the apex of the heart within the framework of the CoreValve TAVR ReValving (Corevalve Inc., Irvine, CA, USA) clinical trial. The self-expanding aortic valve prosthesis is primarily designed for retrograde delivery across the aortic valve. The described transapical approach, however, now allows for treatment in those patients who have, for instance, no adequate "access" in the groin vessels due to peripheral vascular disease. Therefore, its feasibility must be considered as a major step in treating high-risk patients.References
Cribier A, Eltchaninoff H, Bash A, et al. 2002. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation106:3006-8.nGrube E, Laborde JC, Gerckens U, et al. 2006. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in highrisk patients with aortic valve disease: the Siegburg first-in-man study. Circulation114:1616-24.nNashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. 1999. The European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg16:9-13.nWalther T, Falk V, Borger MA, et al. 2007. Minimally invasive transapical beating heart aortic valve implantation—proof of concept. Eur J Cardiothorac Surg31:9-15.n
